From diligence to decision
Technical and scientific was the first step. Today, we are announcing Prudentia Intelligence 2.0 that answers the next set of questions: what does each risk mean for the deal, what to mitigate, and what it means for the strategy.
That full lifecycle of dealmaking - from risk to mitigation to strategy, has always lived offline: resource-heavy, error-prone, and a hard cap on how many deals S&E and BD teams can pursue. Prudentia now removes these constraints through deeper reasoning, integrated research architecture, and domain-specific workspaces.
Deeper reasoning. No model can reliably reason across an entire evidence base - thousands of trial records, publications, regulatory filings and patents, most of them noise - for any given question. The relevant evidence has to be identified, weighted and connected before the strategic judgment starts. Our upgraded scientific frameworks don’t just detect that a risk exists; they reason about its severity, whether and how it can be mitigated, how it interacts with the structure of the deal, and what it means for the thesis. Risk, then mitigation, then strategy - as one connected line of reasoning a dealmaker can follow and defend.
We’re often asked the question, “can’t we just point an open-source LLM model at this?” We’ve catalogued the ways in which naïve AI fails at this, and the failures are specific for scientific reasoning and critical thinking. They flag a safety signal yet miss the later study that explained it away. They treat a preclinical result as if it carried the weight of a Phase 3 readout. They weigh a press release the same as a peer-reviewed trial. A finding can look damning in isolation and be obsolete the moment you see the full dataset around it. Each of those is a wrong answer that looks perfectly reasonable to an open-source model, which is the most dangerous kind in a deal.
Integrated research architecture that makes reasoning defensible. Reasoning is only as good as what it can see. We’ve expanded Prudentia’s data connectivity so the platform reaches the sources the science actually lives in, and structures them so an agent can use them, and accurately. Where we can connect to a source directly, we do. Where a source is fragmented, gated, or buried, we do the work to bring it in. The point is a single, current, connected evidence base underneath the reasoning, so the answer isn’t just plausible, it’s grounded in authority you can point to. No matter how complex the analysis is, the expert can always get to the specific supporting data. It also lets customers continuously monitor progress, risk and opportunities as the assets mature. Diligence is not just a single point in time, it’s a journey and we support it throughout.
Domain specific workspaces: The clinical picture, the safety profile, the regulatory path, the manufacturing and CMC planning, the competitive and IP position - each is a discipline in its own right, and each reads with the authority of a specialist. So we are expanding these domain-specific workspaces, each with the tools, data, and reasoning tuned to that discipline. Each expert works deep in their own domain, and the platform carries their judgment up into the strategy. These are dynamic expert-specific spaces updated with the latest information necessary to analyze the opportunity. None of this is left to the model alone. Our frameworks are defined by scientists and dealmakers who have run diligence at leading firms and biopharma companies, who set the standard for what mitigation means, adjudicate the hard calls, and run continuous quality control. And they hold across M&A, licensing, and investment diligence - one standard of scientific rigor whatever the structure. Workflows tailored to the person using them: S&E/BD leads, diligence experts, bankers, and investors each get a fit-for-role view.
All of it serves three outcomes: deeper intelligence, faster diligence, and greater confidence.
